BIOEE Stock Overview
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
BB Biotech AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF64.40 |
| 52 Week High | CHF0 |
| 52 Week Low | CHF0 |
| Beta | 0.83 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | n/a |
| 3 Year Change | 31.97% |
| 5 Year Change | 31.97% |
| Change since IPO | -27.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIOEE | CH Capital Markets | CH Market | |
|---|---|---|---|
| 7D | 0% | -4.5% | -2.1% |
| 1Y | n/a | 27.7% | -3.6% |
Return vs Industry: Insufficient data to determine how BIOEE performed against the Swiss Capital Markets industry.
Return vs Market: Insufficient data to determine how BIOEE performed against the Swiss Market.
Price Volatility
| BIOEE volatility | |
|---|---|
| BIOEE Average Weekly Movement | 0% |
| Capital Markets Industry Average Movement | 3.2% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in CH Market | 7.4% |
| 10% least volatile stocks in CH Market | 1.9% |
Stable Share Price: BIOEE has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BIOEE's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 10 | n/a | www.bbbiotech.ch/en/bb-biotech/ |
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology.
BB Biotech AG Fundamentals Summary
| BIOEE fundamental statistics | |
|---|---|
| Market cap | CHF2.29b |
| Earnings (TTM) | -CHF206.61m |
| Revenue (TTM) | CHF35.00k |
Over9,999x
P/S Ratio-11.1x
P/E RatioIs BIOEE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOEE income statement (TTM) | |
|---|---|
| Revenue | CHF35.00k |
| Cost of Revenue | CHF0 |
| Gross Profit | CHF35.00k |
| Other Expenses | CHF206.64m |
| Earnings | -CHF206.61m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 26, 2024
| Earnings per share (EPS) | -3.77 |
| Gross Margin | 100.00% |
| Net Profit Margin | -590,305.71% |
| Debt/Equity Ratio | 13.1% |
How did BIOEE perform over the long term?
See historical performance and comparison